CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting - A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
|<< 1 2 3 4 5 6 7 ...>>|

JOURNAL：CBS2017 Article Link

Make a Voice to the World

CBS2017


Denver - October 29, from 11 to 11:30 a.m., Dr Peter Block gave Prof Shao-Liang Chen from Nanjing First Hospital an in-depth interview in the Colorado Convention Center at TCT2017 (Transcatheter Cardiovascular Therapy conference). Prof Shao-Liang Chen is the initiator of DK Crush-V, which using randomized, prospective, multinational design to evaluate the efficacy and safety of DK crush over provisional side branch stenting for patients with unprotected left main bifurcation lesions.


With the further development of interventional devices , coronary bifurcation lesions remains as the one of the most challenging cardiovascular diseases to be tackled. Varies of treatment strategies need high reliability, high level of evidence before promoted in global clinical practices. With passion and faith for better clinical outcome, Prof Chen and his research team keep working on this issue over ten years, seeking a better treatment strategy  for unprotected left main bifurcation lesions. This time, he share his professional clinical experiences and perspectives with international colleagues about the "Current practice and perspectives on treatment in left main bifurcation in China" at TCT2017.






As the leading event in the fields of left main coronary artery disease and transcatheter valve disease, this year, TCT2017 presents 12 LBCTs and 16 FRIs to cause attention.  The progress of DK-V is one of the most notable results, which will be released on October 30th at 11:40 am, local time (at 1:40 a.m. on November 1, Beijing time).



Important Events at TCT2017





>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top